Global healthcare leader Medtronic recently received approval from the Food and Drug Administration for its Intelli rechargeable neurostimulator, and Vanta, a recharge-free neurostimulator, to treat chronic pain caused by diabetic peripheral neuropathy.
Approximately 30% of those with diabetes experience peripheral neuropathy, a result of damage to the nerves located outside of the brain and spinal cord. The condition negatively affects quality of life for several reasons including worsened mood, social relationships and sleep disturbances.
Medtronic’s neurostimulators for spinal cord stimulation help diabetic peripheral neuropathy sufferers experience significantly less pain compared to just using conventional treatments. The company’s portfolio of rechargeable and recharge-free platforms includes a variety of programming options to personalize each patient’s therapy.
